ASLAN Pharmaceuticals' (ASLN) phase II clinical study of Varlitinib as first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients has failed to meet the primary endpoint of significant reductions in tumor size after 12 weeks of treatment.
from RTT - Biotech http://bit.ly/2sswyHr
via IFTTT
No comments:
Post a Comment